Stockscreener 앱 받기
7.85
0.63%
-0.05
시간 외 거래:
7.85
전일 마감가:
$7.90
열려 있는:
$7.82
하루 거래량:
637.48K
Relative Volume:
0.66
시가총액:
$395.55M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.4924
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
-4.15%
1개월 성능:
-10.18%
6개월 성능:
-4.38%
1년 성능:
-33.98%
1일 변동 폭
$7.72
$8.12
1주일 범위
$7.63
$8.48
52주 변동 폭
$5.035
$13.48
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.85 | 414.70M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Can REGENXBIO Inc. expand its profit marginsSafe Growth Small Cap Picks - thegnnews.com
These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts - Yahoo Finance
REGENXBIO Inc. recovery potential after sell offBuy Entry Confirmation Based on Technical Analysis - Newser
When is the best time to exit REGENXBIO Inc.Breakout Screener With Alert Based Timing - Newser
REGENXBIO (NASDAQ:RGNX) Stock Price Passes Below Fifty Day Moving Average on Disappointing Earnings - Defense World
Is REGENXBIO Inc. stock a buy or sellElite Portfolio Components - thegnnews.com
Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026 - MSN
Regenxbio: RBC Capital Maintains Outperform, PT Down to $17 from $21 - AInvest
Can REGENXBIO Inc. hit a new high this monthPredictable Entry Strategy With Technical Backing - Newser
Regenxbio price target lowered to $17 from $21 at RBC Capital - TipRanks
RBC Capital lowers Regenxbio stock price target to $17 on quarterly results - Investing.com Australia
Regenxbio's Q2 2025: Key Contradictions on RGX-121 Approval, Manufacturing Plans, and Pivotal Study Design - AInvest
REGENXBIO Inc. (RGNX): Navigating Q2 2025 Challenges with a High-Stakes Gene Therapy Pipeline - AInvest
RBC Cuts Price Target on REGENXBIO to $17 From $21, Keeps Outperform, Speculative Risk - MarketScreener
Transcript : REGENXBIO Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Regenxbio 2025 Q2 Earnings Wider Losses Amid Progress in Gene Therapy Pipeline - AInvest
REGENXBIO Reports Q2 2025 Financial Results and Progress - TipRanks
Forecasting REGENXBIO Inc. price range with options dataExit Strategy Guide With Risk Control Plan - Newser
Regenxbio Inc. shares rise 1.27% after-hours following the initiation of a pivotal Phase IIb/III clinical trial for diabetic retinopathy. - AInvest
Regenxbio: Q2 Earnings Snapshot - The Washington Post
Regenxbio stock maintains Outperform rating at Raymond James on solid cash runway - Investing.com Nigeria
Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips - Investing.com
Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips By Investing.com - Investing.com Canada
Regenxbio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
XtalPi inks pact with Greg Verdine’s DoveTree; Regenxbio, AbbVie update deal - Endpoints News
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy - TipRanks
Regenxbio Incphase IIb/III trial to be initiated for diabetic retinopathy - MarketScreener
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
RegenXBio and AbbVie Amend Collaboration Agreement - TipRanks
Regenxbio Inc earnings missed by $0.44, revenue fell short of estimates - Investing.com South Africa
Biotech firm Regenxbio Q2 net loss widens - MarketScreener
REGENXBIO to advance diabetic retinopathy treatment to Phase IIb/III trial By Investing.com - Investing.com Australia
REGENXBIO Accelerates 3 Late-Stage Gene Therapies: FDA Review, Duchenne Trial Progress, and $363M War Chest - Stock Titan
REGENXBIO's Diabetic Retinopathy Treatment Hits Major Milestone: $200M Payment as Phase IIb/III Trial Launches - Stock Titan
Analyzing drawdowns of REGENXBIO Inc. with statistical toolsLong-Term Safety Investment Analysis Report - Newser
REGENXBIO Inc. Stock Analysis and ForecastAchieve breakthrough performance with smart picks - Jammu Links News
What catalysts could drive REGENXBIO Inc. stock higher in 2025Get alerts on top growth stocks daily - Jammu Links News
What is the dividend policy of REGENXBIO Inc. stockSkyrocketing investment returns - Jammu Links News
How many analysts rate REGENXBIO Inc. as a “Buy”Phenomenal returns - Jammu Links News
What is REGENXBIO Inc. company’s growth strategyAchieve consistent profits with smart trading - Jammu Links News
How strong is REGENXBIO Inc. company’s balance sheetExceptional ROI - Jammu Links News
What institutional investors are buying REGENXBIO Inc. stockFast-track wealth growth - Jammu Links News
Is REGENXBIO Inc. a growth stock or a value stockOutstanding capital returns - Jammu Links News
When is REGENXBIO Inc. stock expected to show significant growthExceptional financial outcomes - Jammu Links News
How volatile is REGENXBIO Inc. stock compared to the marketUnlock powerful portfolio management tools - Jammu Links News
Clear Street Initiates Regenxbio(RGNX.US) With Buy Rating, Announces Target Price $50 - 富途牛牛
What makes REGENXBIO Inc. stock price move sharplyTrack emerging stocks with high growth potential - Jammu Links News
What drives REGENXBIO Inc. stock priceTriple returns potential - Jammu Links News
REGENXBIO to Discuss Q2 2025 Financial Results and Operational Highlights on August 7 - AInvest
Should I hold or sell REGENXBIO Inc. stock in 2025Daily Trading Updates For Smart Trading - Jammu Links News
Bank of New York Mellon Corp Cuts Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):